Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a pall…
| Métrica | PBM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | 15.1% | -39.2% | +54.2% |
| ROA | 13.8% | -30.9% | +44.8% |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
PSYENCE BIOMEDICAL LTD. cotiza a 4.22 USD y tiene una capitalización bursátil de $16M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud